GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Tectonic Therapeutic Inc.
Shares of Tectonic Therapeutic, a biotech focused on GPCR proteins, are a venture bet on its scientific platform. Their price reflects not current revenues, but investors' belief in the potential of this approach for creating new drugs.
Share prices of companies in the market segment - Pharma other
Tectonic Therapeutic (TECX) is a biotech company using its proprietary platform to discover and develop novel biologics targeting GPCR receptors. We classify it as "Other Pharmaceuticals." The chart below shows the dynamics of this cutting-edge, yet risky, biotech sector.
Broad Market Index - GURU.Markets
Tectonic Therapeutic is a biotech company developing antibody-based drugs targeting GPCR receptors. Its innovative approach makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Tectonic compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
TECX - Daily change in the company's share price Tectonic Therapeutic Inc.
Shares of Tectonic, a biopharmaceutical company, exhibit high volatility. Change_co measures the market's reaction to preclinical data. This metric is an important component of formulas on System.GURU.Markets that evaluate innovative early-stage companies.
Daily change in the price of a set of shares in a market segment - Pharma other
Tectonic Therapeutic, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with TECX's performance, which is dependent on clinical trial results, helps assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Tectonic Therapeutic is a biopharmaceutical company specializing in GPCR receptors. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Tectonic's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Tectonic Therapeutic Inc.
Tectonic Therapeutic, Inc.'s annual performance reflects the development of a new class of biologic drugs targeting G protein receptors. Its 12-month market capitalization depends entirely on progress in preclinical studies, where the company must prove the potential of its platform for developing drugs for a wide range of diseases.
Annual dynamics of market capitalization of the market segment - Pharma other
Tectonic Therapeutic, a private biotech company, is developing a new class of biological drugs. Its growth depends on success in clinical trials. Its valuation reflects investor confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tectonic Therapeutics is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Tectonic Therapeutic Inc.
Tectonic's value as a biopharmaceutical company will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news about the progress of clinical trials of its drugs based on its unique platform, on which its future depends.
Monthly dynamics of market capitalization of the market segment - Pharma other
The biotech sector, which focuses on complex protein targets, is a territory of cutting-edge science and high risk. Its market capitalization dynamics, shown in the chart, reflect investors' faith in new scientific approaches. In this environment, companies like Tectonic Therapeutic are conducting their early research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tectonic Therapeutic, a biopharmaceutical company, lives by the laws of science. Its stock price depends on research results, not market cycles. Its performance is completely disconnected from general economic trends, betting on scientific breakthroughs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Tectonic Therapeutic Inc.
Tectonic Therapeutic, an early-stage biotech company developing a new class of biological drugs, is highly dependent on scientific news. Its weekly stock price reflects investors' reaction to preclinical data and confidence in the potential of its scientific platform, which creates high volatility.
Weekly dynamics of market capitalization of the market segment - Pharma other
Early-stage biotech companies like Tectonic are highly speculative. The entire sector is driven by general sentiment and belief in scientific breakthroughs. The chart below illustrates this general backdrop. It allows you to compare how Tectonic's scientific platform appears more promising to investors than that of hundreds of other biotech startups.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Tectonic Therapeutic is a biotech company developing a new class of biological drugs. Its value lies in the potential of its scientific platform. The chart shows that its shares move on research news, completely ignoring overall market fluctuations.
Market capitalization of the company, segment and market as a whole
TECX - Market capitalization of the company Tectonic Therapeutic Inc.
Tectonic Therapeutic's market capitalization chart represents investors' bets on its scientific platform for drug discovery targeting GPCR receptors. Its dynamics will reflect the market's belief that its approach will enable the development of drugs for a wide range of diseases. Its value is an estimate of the potential of this fundamental biological target.
TECX - Share of the company's market capitalization Tectonic Therapeutic Inc. within the market segment - Pharma other
Tectonic Therapeutic is a biotech company developing a new class of biologic drugs targeting GPCR receptors. In the pharmaceutical sector, its market capitalization reflects the potential of its scientific platform to treat a wide range of diseases. The company's market capitalization reflects its bet that its innovative approach will succeed where others have failed.
Market capitalization of the market segment - Pharma other
Here's a chart reflecting the combined weight of the entire pharmaceutical sector. For Tectonic Therapeutic, with its innovative platform targeting GPCR receptors, this line is a map of uncharted territory. The rising chart shows how willing investors are to fund breakthrough scientific approaches that could unlock entirely new classes of drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Tectonic Therapeutic is a biotech company developing drugs targeting GPCR receptors. Its market capitalization reflects a bet on a new scientific approach to treating a wide range of diseases. While its market share is tiny, it represents significant scientific potential.
Book value capitalization of the company, segment and market as a whole
TECX - Book value capitalization of the company Tectonic Therapeutic Inc.
Tectonic Therapeutic is a biotech company developing drugs targeting GPCR receptors. Its book value represents its financial resources for research. It consists of cash that allows the company to develop its scientific platform. How has this research budget changed? The chart below shows.
TECX - Share of the company's book capitalization Tectonic Therapeutic Inc. within the market segment - Pharma other
Tectonic Therapeutic, Inc. is developing a new class of biologics. Its scientific platform requires a modern infrastructure: laboratories equipped to work with GPCR proteins and conduct preclinical studies. The chart shows the company's share of the R&D infrastructure for this complex biopharmaceutical field.
Market segment balance sheet capitalization - Pharma other
Tectonic Therapeutic, a development-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Tectonic Therapeutic's balance sheet isn't its manufacturing plants, but its scientific platform for discovering and developing antibodies targeting GPCR receptors. The company's assets are its intellectual capital and preclinical data. The chart below shows how this knowledge-intensive asset is valued within the biotech sector.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Tectonic Therapeutic Inc.
Tectonic's balance sheet is its R&D capital. Its entire market value is a premium for its scientific platform. Its price is investors' bet that its approach to drug discovery will be successful and lead to blockbusters.
Market to book capitalization ratio in a market segment - Pharma other
Tectonic Therapeutic is a biotech company developing drugs targeting a complex class of GPCR receptors. Its high valuation on this chart reflects its unique scientific platform, which could unlock new therapeutic opportunities.
Market to book capitalization ratio for the market as a whole
Tectonic Therapeutic is a biotech company developing a new class of biological drugs. Its market value is based on the potential of its scientific platform. Like many early-stage companies, its valuation reflects investors' bets on a future scientific breakthrough.
Debts of the company, segment and market as a whole
TECX - Company debts Tectonic Therapeutic Inc.
Tectonic Therapeutic, a biotech company developing drugs targeting GPCR receptors, is in early-stage research. All capital is allocated to research and development. This chart reflects the startup's financial strategy, where all resources are invested in testing a new therapeutic hypothesis, a high-risk endeavor.
Market segment debts - Pharma other
Tectonic Therapeutic is a preclinical biotech company developing drugs targeting GPCR receptors. At this early stage of development, funding is entirely equity-based. This chart illustrates the industry's typical zero-debt financial model, reflecting the high scientific risk.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Tectonic Therapeutic Inc.
Tectonic Therapeutic is a biotech company developing a new class of biological drugs. Its operations are entirely dependent on research funding. This chart shows its level of financial risk. For a company without revenue, any debt is a significant bet on the success of its scientific approach.
Market segment debt to market segment book capitalization - Pharma other
Tectonic Therapeutic is a biotech company developing a new class of biologics targeting GPCR receptors. This is an important but complex area of pharmaceutical development. This chart illustrates how aggressively the sector uses debt to fund R&D, providing context for assessing Tectonic's risks and potential.
Debt to book value of all companies in the market
Tectonic Therapeutic, a preclinical biotech company, is researching a new class of drugs, which requires significant upfront investment in research. This chart, which reflects the overall market debt burden, helps assess the risks. It shows how the company finances its fundamental research without revenue, and how typical this is for innovative biotech companies.
P/E of the company, segment and market as a whole
P/E - Tectonic Therapeutic Inc.
Tectonic Therapeutic is a biotech company developing novel biologics targeting G protein-coupled receptors (GPCRs), an important class of drug targets. This chart shows how investors value its scientific platform. This valuation is based on the potential of its approach to developing new treatments.
P/E of the market segment - Pharma other
Tectonic Therapeutic develops drugs targeting GPCRs. This chart shows the average valuation for the biotech sector. It emphasizes that Tectonic is valued not by revenue, but by the potential of its scientific platform to create a new class of drugs.
P/E of the market as a whole
Tectonic Therapeutic, Inc. is a biopharmaceutical company focused on the discovery and development of a new class of biologic drugs targeting GPCR receptors. This chart reflects the overall risk appetite of investors in the biotech sector. It helps understand whether TECX's valuation is based on the potential of its scientific platform or is moving in tandem with overall industry sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Tectonic Therapeutic Inc.
Tectonic Therapeutic is a biotech company developing a new class of biologic drugs targeting G protein-coupled receptors. This chart reflects the market's speculative expectations for its scientific platform. It is a bet that its approach will lead to the creation of effective drugs for a wide range of diseases.
%20P%2FE%20Tectonic%20Therapeutic%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Tectonic-Therapeutic-Inc.&v=1772634865822 "Chart of the company's future (projected) P/E Tectonic Therapeutic Inc.")
Future (projected) P/E of the market segment - Pharma other
Tectonic Therapeutic is a biotechnology company developing a new class of biologics targeting G protein-coupled receptors (GPCRs), an important class of drug targets. The data here reflects analysts' collective bet on the success of its scientific platform in developing drugs for a wide range of diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772634865862 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Tectonic Therapeutic is an early-stage biotech company developing a new class of biologics. Their valuation is based on the potential of their scientific platform. This sentiment chart shows how willing investors are to fund fundamental research with a long-term perspective.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772634865902 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Tectonic Therapeutic Inc.
Tectonic Therapeutic is a biotech company specializing in the development of antibodies targeting a class of GPCR receptors implicated in many diseases. This chart shows the financial impact of its cutting-edge research, reflecting investment in a platform that could unlock new therapeutic opportunities.
Profit of companies in the market segment - Pharma other
Tectonic Therapeutic is a biopharmaceutical company developing a new class of biologic drugs targeting G protein-coupled receptors, which play a key role in many diseases. While still in its early stages, its financial history is one of investing in breakthrough science.
Overall market profit
Tectonic Therapeutic is an early-stage biotech company developing a new class of biological drugs. Its value is entirely dependent on the success of its scientific platform. While there is no direct correlation with the economic cycle, the overall market conditions, reflected in this chart, determine the availability of venture capital needed to finance such long-term projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Tectonic Therapeutic Inc.
Tectonic Therapeutic is a biotech company developing novel biologic drugs targeting GPCR receptors. This chart shows analysts' speculative expectations. Future profits depend entirely on the success of their scientific platform in developing effective drugs and advancing them through clinical trials.
%20profit%20of%20the%20company%20Tectonic%20Therapeutic%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Tectonic-Therapeutic-Inc.&v=1772634866030 "Graph of future (projected) profit of the company Tectonic Therapeutic Inc.")
Future (predicted) profit of companies in the market segment - Pharma other
Tectonic Therapeutic is a biotech company developing a new class of biologic drugs targeting G protein-coupled receptors (GPCRs). The pharmaceutical industry profitability projections shown in this chart provide a general overview. This chart helps assess how disruptive Tectonic's platform could be for treating a wide range of diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772634866060 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Tectonic Therapeutic is a biotech company developing a new class of biologic drugs targeting GPCR receptors. Its valuation is based on the potential of its scientific platform. Funding for such cutting-edge research is highly dependent on investor sentiment, which improves with positive economic forecasts, as shown in this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772634866070 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Tectonic Therapeutic Inc.
Tectonic Therapeutic is a biotech company developing novel biologic drugs targeting GPCR receptors. It has no commercial revenue. This chart shows how investors value its scientific platform, which could open up new avenues for treating a wide range of diseases, from obesity to cancer.
P/S market segment - Pharma other
Tectonic Therapeutic is a biotechnology company developing a platform for discovering new biologic drugs targeting the GPCR class of receptors. This metric reflects the average revenue estimate for the sector and helps assess the market premium for a scientific platform capable of unlocking new approaches to treating a wide range of diseases.
P/S of the market as a whole
Tectonic Therapeutic is a biotech company specializing in the discovery and development of new drugs targeting GPCR receptors. The company uses a proprietary platform to discover new therapeutic targets. This chart provides context for understanding how investors value companies with existing revenues compared to biotechs with advanced R&D.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Tectonic Therapeutic Inc.
Tectonic Therapeutic is a biotech company developing biologics targeting GPCR receptors. This chart reflects investors' high estimates of its potential future revenue. This valuation is a bet on the success of its scientific platform in developing new drugs for the treatment of a wide range of diseases.
%20P%2FS%20Tectonic%20Therapeutic%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Tectonic-Therapeutic-Inc.&v=1772634866287 "The graph of the company's future (projected) P/S Tectonic Therapeutic Inc.")
Future (projected) P/S of the market segment - Pharma other
Tectonic Therapeutic is a biotech company developing novel biologic drugs targeting GPCR receptors. This chart compares market expectations for its future revenue with those of other pharmaceutical companies. This valuation reflects investor confidence in its scientific platform for developing treatments for a wide range of diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772634866318 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Tectonic Therapeutic is a preclinical biotechnology company developing a novel platform for the creation of biologic drugs. Its value is based entirely on the potential of its science. This graph of overall market expectations is irrelevant to Tectonic, as its future is determined by the success of its research, not economic cycles.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772634866345 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Tectonic Therapeutic Inc.
This chart shows the revenue of Tectonic Therapeutic, an early-stage biotech focused on developing drugs targeting the GPCR class of proteins. Being in the preclinical stage, the company has no sales revenue. The chart confirms this, and its entire value lies in the potential of its scientific platform.
Sales of companies in the market segment - Pharma other
Tectonic Therapeutic is a biotech company developing a new class of biologics targeting GPCR receptors, an important class of proteins implicated in many diseases. This chart shows revenue in the Other Pharmaceuticals sector. It reflects the cutting edge of science, where Tectonic's platform could open new avenues for treating a wide range of diseases.
Overall market sales
Tectonic Therapeutic is a biotech company developing drugs targeting GPCR receptors. Its value is determined by progress in scientific research. The overall economic situation shown in this chart does not affect the scientific process, but it does provide the backdrop for attracting investment into the biotech sector, which is necessary to fund research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Tectonic Therapeutic Inc.
Tectonic Therapeutic is a preclinical biotechnology company developing a novel class of biologic drugs targeting GPCR receptors. This revenue projection is purely speculative. It reflects analysts' confidence in the scientific potential of its platform and its potential to lead to commercialization.
%20sales%20of%20the%20company%20Tectonic%20Therapeutic%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Tectonic-Therapeutic-Inc.&v=1772634866425 "Schedule of future (projected) sales of the company Tectonic Therapeutic Inc.")
Future (projected) sales of companies in the market segment - Pharma other
Tectonic Therapeutic is a biotechnology company developing a new class of biologic drugs targeting G protein-coupled receptors (GPCRs), which are implicated in many diseases. This chart shows projected revenues for the entire pharmaceutical sector, reflecting the search for innovative approaches to drug development for difficult-to-reach targets.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772634866450 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Tectonic Therapeutic is a biotechnology company developing a new class of biological drugs. Its future depends entirely on success in preclinical and clinical trials. A positive financial market environment, which often accompanies economic growth, is essential for attracting the capital needed to develop its scientific platform.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772634866469 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Tectonic Therapeutic Inc.
Tectonic Therapeutic is a biotech company developing a new class of biologic drugs targeting G protein-coupled receptors. It is in the early, preclinical stage. This chart illustrates the cost of fundamental research, showing the amount of investment the company is making to create and validate its innovative platform.
Market segment marginality - Pharma other
Tectonic Therapeutic is a biotechnology company specializing in the discovery and development of a new class of biologic drugs targeting GPCR receptors. This chart reflects its financial performance. For a preclinical company, the comparison with the sector demonstrates how effectively it manages its initial R&D costs.
Market marginality as a whole
Tectonic Therapeutic is a biotechnology company developing a new class of biological drugs for the treatment of a wide range of diseases. Its success is determined not by economic cycles, but by scientific progress and clinical trial results. The potential of its drug discovery platform is a key value driver.
Employees in the company, segment and market as a whole
Number of employees in the company Tectonic Therapeutic Inc.
Tectonic Therapeutic is a biotech company developing drugs targeting GPCR receptors. This graph shows a small team of scientists. A small staff is typical for a preclinical company. Growth will indicate successful progress on its scientific platform and progress toward clinical trials.
Share of the company's employees Tectonic Therapeutic Inc. within the market segment - Pharma other
Tectonic Therapeutic is a biotech company focused on developing drugs targeting GPCR receptors. While in the research stage, it has a small but highly qualified scientific team. This graph illustrates its focus on science: its minimal staff means all the value is concentrated in its innovative platform.
Number of employees in the market segment - Pharma other
Tectonic Therapeutic is a biotech company developing drugs targeting GPCR receptors, one of the most important classes of drug targets. This graph shows the early, science-intensive stage of fundamental research. A small team of scientists is working to create a drug discovery platform, and its success will determine the company's future growth.
Number of employees in the market as a whole
Tectonic Therapeutic is a biotech company developing a new class of biologics targeting GPCR receptors. Its staff includes a team of highly qualified scientists. This employment chart serves as a backdrop, demonstrating that companies at the forefront of science create unique jobs, and their growth is driven by scientific progress, not the state of the economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Tectonic Therapeutic Inc. (TECX)
Tectonic Therapeutic is a biotech company developing a new class of biologic drugs targeting GPCR receptors, which play a key role in many diseases. This chart shows the enormous market value per scientist. This reflects the market's high valuation of the company's unique scientific platform, not its current operations.
%20of%20the%20company%20Tectonic%20Therapeutic%20Inc.%20(TECX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Tectonic-Therapeutic-Inc.-TECX&v=1772634866940 "Chart of market capitalization per employee (in thousands of dollars) of the company Tectonic Therapeutic Inc. (TECX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Tectonic Therapeutic is a biotech company developing a novel platform for creating drugs targeting GPCR receptors. In this complex area of biology, this metric reflects the market's confidence in their scientific breakthrough. The high cost per employee suggests that investors see enormous potential in their technology for developing drugs for a wide range of diseases.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772634866952 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Tectonic Therapeutic is a biotechnology company developing a new class of biological drugs. This metric reflects a business at the cutting edge of science. Its market capitalization is based on the potential of its scientific platform. Even a small team of scientists can be worth hundreds of millions if their technology is recognized as promising.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772634866980 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Tectonic Therapeutic Inc. (TECX)
Tectonic Therapeutic is a preclinical biotech company focused on GPCR receptors. This is fundamental science. They are not profitable. This graph shows the loss per employee. This is the cost of maintaining an R&D team working on the development of a fundamentally new class of drugs.
%20Chart%20Tectonic%20Therapeutic%20Inc.%20(TECX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Tectonic-Therapeutic-Inc.-TECX&v=1772634866999 "Company Profit Per Employee (in thousands of dollars) Chart Tectonic Therapeutic Inc. (TECX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Tectonic Therapeutic is a clinical-stage biotech company specializing in drug discovery targeting G protein receptors. The company has no profit, only R&D expenses. This metric reflects R&D capital burn per employee, which is compared to industry standards for assessing research intensity.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772634867006 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Tectonic Therapeutic is a preclinical biotech company working on GPCRs. This is fundamental science, requiring elite specialists. This chart doesn't show profits; it shows the amount of investment burned per scientist to fund and develop this cutting-edge, yet highly risky, scientific platform.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772634867016 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Tectonic Therapeutic Inc. (TECX)
Tectonic Therapeutic is a biotech company developing a new class of biologics targeting GPCR receptors. This schedule is typical for a company in the preclinical stage. The lack of revenue per employee means all resources are focused on developing their innovative scientific platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Tectonic-Therapeutic-Inc.-TECX&v=1772634867027 "Sales chart per company employee Tectonic Therapeutic Inc. (TECX)")
Sales per employee in the market segment - Pharma other
Tectonic Therapeutic (TECX) is a biotech company developing a drug discovery platform targeting GPCR receptors (an important class of receptors in the body). This graph shows the revenue (if any) generated by each employee (scientist). It's an indicator of the productivity of their early-stage R&D platform.
Sales per employee for the market as a whole
Tectonic Therapeutic (TECX) is a biopharmaceutical company developing a drug discovery platform targeting GPCR receptors. This is an early-stage (preclinical) R&D company. The company has no revenue, and its revenue is close to zero.
Short shares by company, segment and market as a whole
Shares shorted by company Tectonic Therapeutic Inc. (TECX)
Tectonic Therapeutic is a preclinical biotech developing drugs targeting GPCR receptors. This chart reflects bearish bets. Bearish bets are taking an extremely high risk: the company's technology has not been tested in humans, and it will be years before any significant data is available.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Tectonic-Therapeutic-Inc.-TECX&v=1772634867111 "Short Shares Chart for the Company Tectonic Therapeutic Inc. (TECX)")
Shares shorted by market segment - Pharma other
Tectonic Therapeutics is a biotech company developing a platform for creating drugs targeting GPCR receptors. This chart shows bearish sentiment. The "shorts" here are betting that their scientific platform will fail to produce successful drug candidates.
Shares shorted by the overall market
Tectonic Therapeutic is a biotech company developing drugs that target GPCR receptors (key "switches" in cells). This is fundamental science. This chart reflects the overall market pessimism. When investors panic, they avoid early-stage biotechs that require years and millions of dollars in research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Tectonic Therapeutic Inc. (TECX)
Tectonic Therapeutic (TECX) is an early-stage biotech company using its platform to discover drugs targeting the GPCR class of proteins. This is a speculative R&D bet. This chart measures hype. It shows "overbought" (above 70) on news of partnerships with big pharma or "oversold" (below 30) during periods of no news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Tectonic-Therapeutic-Inc.-TECX&v=1772634867158 "RSI 14 indicator chart for the company's stock Tectonic Therapeutic Inc. (TECX)")
RSI 14 Market Segment - Pharma other
Tectonic (TECX) is a biotech company working on complex targets (GPCRs) for drug discovery (immunology, oncology). The RSI_14_Seg for "Pharma Other" (biotech) shows the overall sentiment. The chart helps us understand: is TECX's volatility a reaction to their trials, or is the entire sector overheated?
RSI 14 for the overall market
Tectonic Therapeutic (TECX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TECX (Tectonic Therapeutic Inc.)
Tectonic Therapeutic is a biotech company developing drugs targeting GPCRs (G protein-coupled receptors), a key class of drug targets. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of their early-stage scientific platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TECX-Tectonic-Therapeutic-Inc.&v=1772634867221 "A chart showing analyst consensus forecasts for the expected stock price. TECX (Tectonic Therapeutic Inc.)")
The difference between the consensus estimate and the actual stock price TECX (Tectonic Therapeutic Inc.)
Tectonic Therapeutic is a biotech company using a deep understanding of GPCR receptors to develop new drugs (including those for obesity). This chart shows how the current stock price differs from the "fair" value predicted by analysts. It reflects their faith in this complex yet promising scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TECX-Tectonic-Therapeutic-Inc.&v=1772634867276 "A chart showing the difference between the consensus forecast and the actual stock price. TECX (Tectonic Therapeutic Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Tectonic Therapeutic is a biotech company using its platform to discover new drugs targeting GPCR receptors (key "switches" in cells). This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe in the success of this complex R&D platform.
Analysts' consensus forecast for the overall market share price
Tectonic Therapeutic is a biotech company specializing in developing drugs targeting GPCR receptors (key "switches" in cells) to treat a wide range of diseases. This chart shows the company's overall risk appetite. For Tectonic, an early-stage company with an innovative platform, overall market optimism is critical for funding R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Tectonic Therapeutic Inc.
Tectonic Therapeutic (TECX) is a biotech company working on elusive targets—GPCRs. They use their R&D platform to develop new drugs (antibodies) against these challenging targets in immunology and oncology. This chart is a pure reflection of their science. Its performance depends entirely on their progress in preclinical studies and their confidence in their platform.
AKIMA Market Segment Index - Pharma other
Tectonic (TECX) is a clinical-stage biotech and a pioneer in GPCR research; the company (like Septerna) is using its R&D platform to develop a new generation of drugs targeting this critical class of receptors. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough (GPCR) R&D platform (TECX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Tectonic Therapeutic is a biotech company developing biologics targeting GPCR receptors (previously difficult-to-reach targets). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative scientific platform compares to the broader economic trends affecting biotech.
